Haitham Abdelhakim
Overview
Explore the profile of Haitham Abdelhakim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bansal R, Wiedel A, Hastings R, Boutz F, Abdelhakim H, Ahmed N, et al.
J Clin Apher
. 2025 Jan;
40(1):e70004.
PMID: 39810305
Apheresis is essential to conducting hematopoietic cell transplantation and genetically engineered cellular therapy procedures. Many patients and donors require central venous catheter (CVC) access for apheresis due to lack of...
2.
Lee A, Godwin A, Abdelhakim H
Extracell Vesicles Circ Nucl Acids
. 2024 Dec;
5(2):329-343.
PMID: 39639879
Extracellular vesicles (EVs) contribute to the development of cancer in various ways. Non-Hodgkin lymphoma (NHL) is a cancer of mature lymphocytes and the most common hematological malignancy globally. The most...
3.
McGuirk M, Shahzad M, Amin M, Khan M, Bellman P, Mudaranthakam D, et al.
Transpl Immunol
. 2024 Mar;
84:102039.
PMID: 38513813
Background: We aimed to investigate factors associated with cytomegalovirus (CMV) viremia and CMV disease and its impact on post-transplant outcomes including overall survival (OS) following allogeneic hematopoietic stem cell transplantation...
4.
Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq A, et al.
Crit Rev Oncol Hematol
. 2024 Feb;
196:104310.
PMID: 38423375
We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in TP53-mutated myelodysplastic syndromes (MDS). A literature search was performed on PubMed, Cochrane,...
5.
Mushtaq M, Shahzad M, Amin M, Lutfi F, DeJarnette S, Al-Ramahi J, et al.
Leuk Lymphoma
. 2024 Jan;
65(4):493-502.
PMID: 38164945
We investigated the outcomes after adult haploidentical (haplo) and matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) in a single-center study ( = 452) including 276 MUD and 176 haplo...
6.
Al-Ramahi J, Shahzad M, Nguyen A, Li K, Amin M, Ahmed N, et al.
Bone Marrow Transplant
. 2023 Oct;
59(1):134-137.
PMID: 37833526
No abstract available.
7.
Ahmed N, Wesson W, Mushtaq M, Bansal R, Abdelhakim H, Bromert S, et al.
Front Oncol
. 2023 Aug;
13:1206715.
PMID: 37601685
Background: The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy. Despite the promising...
8.
Al-Ramahi J, Shahzad M, Li K, DeJarnette S, Chaudhary S, Lutfi F, et al.
Leuk Lymphoma
. 2023 Aug;
64(12):1981-1991.
PMID: 37574842
We investigated the outcomes after Coronavirus disease 2019 (COVID) in hematopoietic cell transplant (HCT) or chimeric antigen receptor-T cell (CART) therapy recipients in a single-centre study including all ( = ...
9.
Tabak C, Hyter S, Yacoub A, Byrd K, McGuirk J, Godwin A, et al.
Front Oncol
. 2023 Apr;
13:1017230.
PMID: 37007115
Acute myeloid leukemia (AML) is a complex diagnosis that puts patients at a higher risk for developing infections, particularly invasive fungal infections (IFI). Mutations in have been shown to cause...
10.
Shahzad M, Chaudhary S, Tariq E, Mushtaq A, Anwar I, Ahmed N, et al.
Leuk Lymphoma
. 2022 Oct;
64(2):273-282.
PMID: 36282773
We systematically evaluated the primary and secondary endpoints used in acute myeloid leukemia (AML) phase III randomized controlled trials (RCTs). We included 238 phase III AML RCTs in the past...